NASDAQ:CBMG - Cellular Biomedicine Group Stock Price, News & Analysis

$13.48
+1.10 (+8.89 %)
(As of 08/18/2019 09:05 AM ET)
Today's Range
$12.59
Now: $13.48
$13.55
50-Day Range
$11.93
MA: $13.92
$16.53
52-Week Range
$11.63
Now: $13.48
$25.00
Volume42,500 shs
Average Volume28,274 shs
Market Capitalization$259.49 million
P/E RatioN/A
Dividend YieldN/A
Beta2.7
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CBMG
CUSIPN/A
Phone408-973-7884

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$220,000.00
Book Value$4.27 per share

Profitability

Net Income$-38,930,000.00
Net Margins-17,921.62%

Miscellaneous

Employees193
Market Cap$259.49 million
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive CBMG News and Ratings via Email

Sign-up to receive the latest news and ratings for CBMG and its competitors with MarketBeat's FREE daily newsletter.


Cellular Biomedicine Group (NASDAQ:CBMG) Frequently Asked Questions

What is Cellular Biomedicine Group's stock symbol?

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

How were Cellular Biomedicine Group's earnings last quarter?

Cellular Biomedicine Group Inc (NASDAQ:CBMG) issued its quarterly earnings results on Tuesday, August, 6th. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.53) by $0.10. Cellular Biomedicine Group had a negative net margin of 17,921.62% and a negative return on equity of 44.32%. View Cellular Biomedicine Group's Earnings History.

When is Cellular Biomedicine Group's next earnings date?

Cellular Biomedicine Group is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Cellular Biomedicine Group.

What price target have analysts set for CBMG?

3 equities research analysts have issued 1-year target prices for Cellular Biomedicine Group's stock. Their predictions range from $26.00 to $38.00. On average, they expect Cellular Biomedicine Group's stock price to reach $30.3333 in the next year. This suggests a possible upside of 125.0% from the stock's current price. View Analyst Price Targets for Cellular Biomedicine Group.

What is the consensus analysts' recommendation for Cellular Biomedicine Group?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellular Biomedicine Group.

Has Cellular Biomedicine Group been receiving favorable news coverage?

News headlines about CBMG stock have trended negative on Sunday, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Cellular Biomedicine Group earned a news impact score of -2.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Cellular Biomedicine Group.

Are investors shorting Cellular Biomedicine Group?

Cellular Biomedicine Group saw a decrease in short interest in the month of July. As of July 31st, there was short interest totalling 510,200 shares, a decrease of 5.1% from the June 30th total of 537,400 shares. Based on an average trading volume of 34,600 shares, the short-interest ratio is presently 14.7 days. Approximately 4.6% of the company's stock are sold short. View Cellular Biomedicine Group's Current Options Chain.

Who are some of Cellular Biomedicine Group's key competitors?

What other stocks do shareholders of Cellular Biomedicine Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellular Biomedicine Group investors own include Crispr Therapeutics (CRSP), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Adaptimmune Therapeutics (ADAP), Anthera Pharmaceuticals (ANTH), Editas Medicine (EDIT), Fate Therapeutics (FATE), Nektar Therapeutics (NKTR), Novavax (NVAX) and Viewray (VRAY).

Who are Cellular Biomedicine Group's key executives?

Cellular Biomedicine Group's management team includes the folowing people:
  • Mr. Bizuo Liu, CEO, CFO & Director (Age 54)
  • Dr. Yihong Yao, Chief Scientific Officer (Age 51)
  • Mr. Andrew K. Chan, Chief Legal Officer, Gen. Counsel, Sr. VP of Corp. Bus. Devel. & Sec. (Age 61)
  • Dr. Li Zhang, Chief Production Officer
  • Derrick C. Li, Head of Strategy & Investor Relations

Who are Cellular Biomedicine Group's major shareholders?

Cellular Biomedicine Group's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.89%), Platinum Investment Management Ltd. (3.50%), Nikko Asset Management Americas Inc. (2.77%), Sumitomo Mitsui Trust Holdings Inc. (2.75%), ARK Investment Management LLC (1.63%) and Vanguard Group Inc. (1.10%). Company insiders that own Cellular Biomedicine Group stock include Andrew K Chan, Tony Liu, Wen Tao Liu and Yihong Yao. View Institutional Ownership Trends for Cellular Biomedicine Group.

Which institutional investors are selling Cellular Biomedicine Group stock?

CBMG stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., BNP Paribas Arbitrage SA and Wells Fargo & Company MN. View Insider Buying and Selling for Cellular Biomedicine Group.

Which institutional investors are buying Cellular Biomedicine Group stock?

CBMG stock was purchased by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., BlackRock Inc., AWM Investment Company Inc., ARK Investment Management LLC, Platinum Investment Management Ltd., Northern Trust Corp and Charles Schwab Investment Management Inc.. Company insiders that have bought Cellular Biomedicine Group stock in the last two years include Andrew K Chan, Tony Liu and Yihong Yao. View Insider Buying and Selling for Cellular Biomedicine Group.

How do I buy shares of Cellular Biomedicine Group?

Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellular Biomedicine Group's stock price today?

One share of CBMG stock can currently be purchased for approximately $13.48.

How big of a company is Cellular Biomedicine Group?

Cellular Biomedicine Group has a market capitalization of $259.49 million and generates $220,000.00 in revenue each year. The biotechnology company earns $-38,930,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis. Cellular Biomedicine Group employs 193 workers across the globe.View Additional Information About Cellular Biomedicine Group.

What is Cellular Biomedicine Group's official website?

The official website for Cellular Biomedicine Group is http://www.cellbiomedgroup.com/.

How can I contact Cellular Biomedicine Group?

Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]


MarketBeat Community Rating for Cellular Biomedicine Group (NASDAQ CBMG)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  154 (Vote Outperform)
Underperform Votes:  170 (Vote Underperform)
Total Votes:  324
MarketBeat's community ratings are surveys of what our community members think about Cellular Biomedicine Group and other stocks. Vote "Outperform" if you believe CBMG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBMG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2019 by MarketBeat.com Staff

Featured Article: What is a capital gain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel